CRIS Current Research Information System

GELSOMINO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.417
EU - Europa 1.210
NA - Nord America 1.141
AF - Africa 144
SA - Sud America 99
OC - Oceania 4
Totale 5.015
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.105
VN - Vietnam 677
IT - Italia 615
CN - Cina 614
SG - Singapore 591
HK - Hong Kong 179
NL - Olanda 102
IN - India 96
DE - Germania 88
KR - Corea 82
FR - Francia 64
GB - Regno Unito 61
BR - Brasile 60
SE - Svezia 53
IE - Irlanda 51
CI - Costa d'Avorio 48
FI - Finlandia 46
JP - Giappone 46
CH - Svizzera 37
TG - Togo 28
CA - Canada 24
ZA - Sudafrica 23
RU - Federazione Russa 22
JO - Giordania 21
PH - Filippine 19
TH - Thailandia 19
SC - Seychelles 16
AR - Argentina 15
BG - Bulgaria 15
NG - Nigeria 14
PL - Polonia 14
ID - Indonesia 12
AT - Austria 11
BD - Bangladesh 11
ES - Italia 10
IQ - Iraq 9
MX - Messico 8
TR - Turchia 8
TW - Taiwan 8
PK - Pakistan 7
CL - Cile 6
EC - Ecuador 6
LT - Lituania 6
MA - Marocco 5
VE - Venezuela 5
AU - Australia 4
BE - Belgio 4
OM - Oman 3
PY - Paraguay 3
SA - Arabia Saudita 3
UZ - Uzbekistan 3
CO - Colombia 2
DZ - Algeria 2
JM - Giamaica 2
KG - Kirghizistan 2
KZ - Kazakistan 2
SO - Somalia 2
AL - Albania 1
AZ - Azerbaigian 1
EE - Estonia 1
EG - Egitto 1
ET - Etiopia 1
GE - Georgia 1
GM - Gambi 1
GR - Grecia 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
LB - Libano 1
LI - Liechtenstein 1
LY - Libia 1
MD - Moldavia 1
MN - Mongolia 1
MT - Malta 1
MY - Malesia 1
PE - Perù 1
PR - Porto Rico 1
RS - Serbia 1
SI - Slovenia 1
SN - Senegal 1
SR - Suriname 1
TN - Tunisia 1
UA - Ucraina 1
Totale 5.015
Salva come PNG Salva come JPEG
Città #
Singapore 423
Ashburn 204
Hefei 195
Ho Chi Minh City 190
Hanoi 168
Hong Kong 167
San Jose 125
Bologna 119
Seoul 77
Santa Clara 73
Beijing 72
Milan 60
Dublin 51
New York 50
Dallas 49
Abidjan 48
Boardman 38
Chandler 38
Los Angeles 33
Tokyo 31
Lomé 28
Bern 27
Helsinki 26
Rome 26
Turin 24
Vicenza 24
Munich 23
Cinquefrondi 22
Lauterbourg 22
Amman 21
Council Bluffs 21
Haiphong 21
Da Nang 20
Visakhapatnam 20
Bengaluru 17
Frankfurt am Main 16
Johannesburg 16
Messina 16
The Dalles 16
Hyderabad 15
Shanghai 15
Buffalo 14
Sofia 14
Turku 14
Abeokuta 13
Guangzhou 13
Modena 13
Redondo Beach 13
Southend 13
Biên Hòa 12
Fairfield 12
Princeton 12
Seattle 12
Houston 11
London 11
Paris 11
Quận Bình Thạnh 11
Amsterdam 10
Bắc Ninh 10
Chicago 10
Tianjin 10
Warsaw 10
Bắc Giang 9
Toronto 9
Ferrara 8
Hải Dương 8
Jakarta 8
Montreal 8
Phoenix 8
Tongling 8
Vinh 8
Atlanta 7
Boydton 7
Cesena 7
Mumbai 7
Orem 7
Phủ Lý 7
São Paulo 7
Vũng Tàu 7
Bangkok 6
Ha Long 6
Naples 6
Nha Trang 6
Ninh Bình 6
Poplar 6
Redmond 6
Rimini 6
San Francisco 6
Xi'an 6
Berlin 5
Can Tho 5
Falkenstein 5
Guayaquil 5
Lappeenranta 5
Manila 5
Palermo 5
Quận Một 5
Ravenna 5
Vienna 5
Wilmington 5
Totale 3.141
Salva come PNG Salva come JPEG
Nome #
Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLC 285
The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy 267
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary 257
A phase II, open-label, single arm, trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale 233
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1- rearranged NSCLC 211
Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience 197
Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes 196
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations 194
Genetic Characterization of Cancer of Unknown Primary Using Liquid Biopsy Approaches 184
Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors 180
From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC) 179
Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: A case report within the experience of a single institution 168
PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors 159
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed 148
Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC) 141
STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive? 127
Ad(aura): a fresh breeze for patients with resected EGFR-mutant non-small cell lung cancer 125
Early monitoring of plasma KRAS G12C with digital PCR predicts antitumor response to immunotherapy or sotorasib in advanced NSCLC: A brief report 125
Histopathological Evidence for a Non-Inflammatory Mechanism in Osimertinib-Induced Myopathy: A Case Report 121
Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinib 113
Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis 113
PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis 113
Predictors of Survival to Immunotherapy and Chemoimmunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis 106
Paraneoplastic vs. non-paraneoplastic anti-Hu associated dysmotility: a case series and literature review 104
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 99
First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis 91
A new classification of upper gastrointestinal toxicity induced by immunotherapy: from endoscopic and pathological insights to clinical management 88
PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: The role of salvage chemo-immunotherapy combination 86
PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategy 85
A case series of non-small cell lung cancer patients with EGFR or HER2 exon 20 insertion in Li Fraumeni syndrome 76
Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) (British Journal of Cancer, (2020), 123, 1, (26-32), 10.1038/s41416-020-0845-3) 74
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines) 74
Should We Test Cancer Susceptibility Genes in Routinely Used Multigene Panels? A Case of Synchronous Lung Adenocarcinoma and Breast Cancer Associated With Germline CHEK2 Mutation 73
Neurological Manifestations as a Harbinger of Myocarditis in Patients Treated With Immune Checkpoint Inhibitors 71
Prognostic relevance of pleural invasion for resected NSCLC patients undergoing adjuvant treatments: A propensity score-matched analysis of SEER database 70
Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY 65
The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer 45
Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50% 39
First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC 37
Totale 5.119
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.156
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.156
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022186 0 10 2 15 3 2 0 54 8 8 58 26
2022/2023530 14 39 19 19 89 41 45 37 110 23 29 65
2023/2024255 17 16 11 23 19 52 9 31 6 36 31 4
2024/20251.225 54 77 84 92 131 75 136 58 33 113 128 244
2025/20262.923 409 440 232 234 235 117 281 111 522 223 119 0
Totale 5.119